U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Sekisui Medical Co., Ltd. - 507037 - 10/05/2017
  1. Warning Letters

CLOSEOUT LETTER

Sekisui Medical Co., Ltd. MARCS-CMS 507037 —

Recipient:
Sekisui Medical Co., Ltd.

United States

Issuing Office:

United States

 

   

Black HHS-Blue FDA Logo

 

 
 
10903 New Hampshire Avenue
Silver Spring, MD 20993 

October 5, 2017

Mr. Homare Tachiyanagi, General Manager
Sekisui Medical Co. Ltd.
Iwate Fractory
4-11 5 Matsuo
Hachimantai. Iwate. 028-7305
Japan

Reference: FET 3002806840
 

Dear Mr. Tachiyanagi:
 

The Food and Drug Administration (FDA) has completed an evaluation of your firm's corrective actions in response to our Warning Letter: 320-17-04 dated November 8, 2016. Based on our evaluation, it appears that you have addressed the deviations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter docs not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The FDA expects you and your firm to maintain compliance with current good manufacturing practices and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should deviations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Runa Musib, Ph.D.
Compliance Officer
Division of Drug Quality II

Back to Top